Actively Recruiting
Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer
Led by Fudan University · Updated on 2024-07-08
10
Participants Needed
1
Research Sites
36 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a Phase II, open-label, single-arm study evaluating the efficacy and safety of combined treatment of dasatinib, quercetin with chemotherapy in mTNBC (triple negative breast cancer) patients who progressed during previous chemotherapy.
CONDITIONS
Official Title
Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female aged 18 to 70 years
- ECOG Performance Status of 0 or 1
- Metastatic or locally advanced triple-negative breast cancer documented by tissue analysis
- Evidence of cancer recurrence or progression after chemotherapy for metastatic breast cancer
- Adequate blood counts and organ function based on lab tests within 14 days before starting treatment
- Women of childbearing potential agree to abstain or use contraception as specified
- Measurable disease according to RECIST v1.1 criteria
- Ability to understand the study and willingness to participate and be followed up
You will not qualify if you...
- Symptomatic, untreated, or actively progressing brain metastases
- Active or past autoimmune disease or immune deficiency
- Significant heart disease
- Other cancers within 5 years before screening, except those with very low risk of spread or death
- Chemotherapy, radiotherapy, immunotherapy, or surgery (except minor outpatient surgery) within 3 weeks before study treatment
- Pregnancy, breastfeeding, or planning pregnancy during the study
- Known allergies to any study drug components
- Long-term oral steroid hormone use, requiring a 4-week stop if used occasionally in the past
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
270 Dongan Road, Fudan University Shanghai Cancer Center
Shanghai, China, 200032
Actively Recruiting
Research Team
Z
Zhimin Shao, MD, PhD
CONTACT
Y
Yin Liu, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here